Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Incyte Corporation is the lead sponsor of 59 current clinical trials in our USA, UK, China, Ireland and EU (CTIS) registers. 28 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Ruxolitinib, Povorcitinib and Axatilimab. The most-studied condition is Solid Tumors.

ClinicalTrials.gov trials by status

Recruiting2853%
Active, closed2547%

Trials by phase

Phase 32140%
Phase 11630%
Phase 21019%
Phase 1/236%
Observational36%

Clinical trials sponsored by Incyte Corporation

53 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia NCT07623200 · Essential Thrombocythemia Drug: INCA033989	Phase 3	Recruiting	2026-09	UK, USA
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease NCT06585774 · ClinicalTrials.gov ↗ · Chronic Graft-versus-host-disease Drug: Axatilimab	Phase 3	Recruiting	2025-01	Ireland, UK, USA
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) NCT07124078 · Chronic Graft-versus-host-disease Drug: Axatilimab	Phase 2	Recruiting	2026-05	UK, USA
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors NCT05836324 · Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors Drugs: ADG126, Bevacizumab, Cetuximab	Phase 1	Recruiting	2023-07	UK, USA, China
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression NCT07214779 · ClinicalTrials.gov ↗ · Ovarian Cancer Drug: INCB123667	Phase 3	Recruiting	2025-12	Ireland, UK, USA
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa NCT07213973 · Hidradenitis Suppurativa (HS) Drug: Povorcitinib	Phase 2	Recruiting	2026-02	USA
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo NCT06804811 · ClinicalTrials.gov ↗ · NonSegmental Vitiligo Drug: Ruxolitinib	Phase 3	Recruiting	2025-11	UK
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders NCT07104565 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia	Phase 2	Recruiting	2025-12	UK, USA
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma NCT07522073 · ClinicalTrials.gov ↗ · Solid Tumors Drug: INCB161734	Phase 3	Recruiting	2026-04	UK, USA
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib NCT06855498 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa (HS) Drug: Povorcitinib	Phase 3	Recruiting	2025-02	UK, USA
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease NCT05919511 · cGVHD	Observational	Recruiting	2023-08	USA
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression NCT07023627 · ClinicalTrials.gov ↗ · Ovarian Cancer Drug: INCB123667	Phase 2	Recruiting	2025-11	UK, USA
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva NCT05090891 · ClinicalTrials.gov ↗ · Fibrodysplasia Ossificans Progressiva (FOP) Drug: INCB000928	Phase 2	Recruiting	2022-05	UK, USA, China
Study of INCA036978 in Participants With Myeloproliferative Neoplasms NCT07441694 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasms	Phase 1	Recruiting	2026-05	UK, USA
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer NCT07284849 · ClinicalTrials.gov ↗ · CRC (Colorectal Cancer) Drugs: Bevacizumab, Folfox, INCA33890	Phase 3	Recruiting	2026-03	UK, USA, China
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms NCT06034002 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasms	Phase 1	Recruiting	2023-12	USA
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis NCT06627335 · ClinicalTrials.gov ↗ · Pregnancy Related, Atopic Dermatitis Drug: Ruxolitinib	Observational	Recruiting	2023-03	USA
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease NCT07559396 · ClinicalTrials.gov ↗ · Renal Impairment Drug: INCB123667	Phase 1	Recruiting	2026-05	USA
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) NCT06615050 · ClinicalTrials.gov ↗ · Graft-versus-host Disease (GVHD) Drugs: Cyclophosphamide, Methotrexate, Mycophenolate Mofetil	Phase 3	Recruiting	2025-04	USA
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916 · ClinicalTrials.gov ↗ · Solid Tumors, Hematologic Malignancies	Phase 1	Recruiting	2026-01	USA
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo NCT06548360 · ClinicalTrials.gov ↗ · NonSegmental Vitiligo Drug: Ruxolitinib	Phase 3	Recruiting	2025-01	USA
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment NCT07559474 · ClinicalTrials.gov ↗ · Hepatic Insufficiency, Liver Diseases Drug: INCB123667	Phase 1	Recruiting	2026-05	USA
A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants NCT07588139 · ClinicalTrials.gov ↗ · Healthy Participants Drugs: Povorcitinib, Ruxolitinib	Phase 1	Recruiting	2026-05	USA
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06179160 · ClinicalTrials.gov ↗ · Solid Tumors Drugs: Cetuximab, Folfiri, Folfox	Phase 1	Recruiting	2024-01	USA
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population NCT06259669 · ClinicalTrials.gov ↗ · Pregnancy Related, Atopic Dermatitis Drug: Ruxolitinib	Observational	Recruiting	2023-09	USA
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms NCT07008118 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasms	Phase 1	Recruiting	2025-10	USA
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants NCT07448155 · ClinicalTrials.gov ↗ · Healthy Participants Drug: INCA033989	Phase 1	Recruiting	2026-03	USA
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa NCT07049575 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa Drug: Ruxolitinib	Phase 1	Recruiting	2025-11	USA
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) NCT06958211 · Hidradenitis Suppurativa Drug: Ruxolitinib	Phase 3	Active, closed	2025-06	USA
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. NCT04680052 · Follicular Lymphoma, Marginal Zone Lymphoma Drugs: Lenalidomide, Rituximab, Tafasitamab	Phase 3	Active, closed	2021-04	Ireland, UK, USA, China
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients NCT04824092 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma Drugs: Cyclophosphamide, Doxorubicin, Lenalidomide	Phase 3	Active, closed	2021-05	Ireland, UK, USA
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa NCT06212999 · Hidradenitis Suppurativa (HS) Drug: Povorcitinib	Phase 3	Active, closed	2024-01	UK, USA
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) NCT05429268 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Drugs: Lenalidomide, Tafasitamab	Phase 3	Active, closed	2022-12	Ireland, UK
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy NCT06821542 · ClinicalTrials.gov ↗ · Chronic Graft-versus-host-disease Drug: Axatilimab	Phase 3	Active, closed	2025-06	Ireland, UK
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms NCT06313593 · Myeloproliferative Neoplasms	Phase 1	Active, closed	2024-08	UK, USA
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms NCT05936359 · ClinicalTrials.gov ↗ · Myeloproliferative Neoplasms Drugs: INCA033989, Ruxolitinib	Phase 1	Active, closed	2023-09	UK
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders NCT04455841 · ClinicalTrials.gov ↗ · Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis Drugs: INCB000928, Ruxolitinib	Phase 1/2	Active, closed	2021-03	UK, USA
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) NCT06113445 · NonSegmental Vitiligo Drug: Povorcitinib	Phase 3	Active, closed	2023-11	USA
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease NCT06388564 · ClinicalTrials.gov ↗ · Chronic Graft-versus-host-disease Drugs: Axatilimab, Ruxolitinib	Phase 2	Active, closed	2024-10	UK, USA
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) NCT06113471 · ClinicalTrials.gov ↗ · NonSegmental Vitiligo Drug: Povorcitinib	Phase 3	Active, closed	2023-11	UK, USA
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) NCT04509700 · ClinicalTrials.gov ↗ · B-Cell Malignancies Drugs: Ibrutinib, Ruxolitinib	Phase 2	Active, closed	2020-08	UK, USA
Study of INCB123667 in Subjects With Advanced Solid Tumors NCT05238922 · ClinicalTrials.gov ↗ · Solid Tumors Drugs: Bevacizumab, Fulvestrant, Olaparib	Phase 1	Active, closed	2022-07	UK, USA
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms NCT04279847 · ClinicalTrials.gov ↗ · Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome Drug: Ruxolitinib	Phase 1	Active, closed	2021-02	UK, USA, China
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06818812 · ClinicalTrials.gov ↗ · Solid Tumors Drugs: Cetuximab, GEMNabP, MFOLFIRINOX	Phase 1	Active, closed	2025-03	USA
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma NCT05851443 · ClinicalTrials.gov ↗ · Moderate to Severe Asthma Drugs: Ics-Laba, Povorcitinib	Phase 2	Active, closed	2023-07	USA
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) NCT06516965 · ClinicalTrials.gov ↗ · Prurigo Nodularis Drug: Povorcitinib	Phase 3	Active, closed	2024-10	UK, USA
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis NCT06832618 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drug: Ruxolitinib	Phase 3	Active, closed	2025-06	UK, USA
Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients NCT05222555 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma Drugs: Lenalidomide, Tafasitamab	Phase 1/2	Active, closed	2022-07	USA
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive NCT05879822 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Active, closed	2023-10	China
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) NCT06516952 · ClinicalTrials.gov ↗ · Prurigo Nodularis Drug: Povorcitinib	Phase 3	Active, closed	2024-10	USA
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib NCT02955940 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer Drugs: Capecitabine, Regorafenib, Ruxolitinib	Phase 2	Active, closed	2016-11	USA
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) NCT06959225 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa Drug: Ruxolitinib	Phase 3	Active, closed	2025-06	USA
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD NCT06843408 · ClinicalTrials.gov ↗ · Chronic Graft-versus-host-disease Drug: Axatilimab	Phase 1/2	Active, closed	2025-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Incyte Corporation in the EU trials register (CTIS)

6 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Incyte Corporation as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2) 2025-522748-42-00 · CTIS ↗ · Neoplasms Drugs: Doxorubicin, Gemcitabine, Paclitaxel	Phase 3	Ongoing	Ireland + 7 more
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms 2026-525217-31-00 · Neoplasms	Phase 1	Authorised	Italy, Belgium, Germany + 2 more
A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms 2026-525360-18-00 · Neoplasms	Phase 1	Authorised	Italy, Belgium, Germany
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303) 2025-525009-18-00 · CTIS ↗ · Neoplasms Drugs: Fluorouracil, Gemcitabine, INCB161734	Phase 3	Ongoing	Poland, Italy, Netherlands + 9 more
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies 2025-523130-11-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Italy, Belgium, Denmark
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer 2025-523735-19-00 · CTIS ↗ · Neoplasms Drugs: Bevacizumab, Calcium folinate, Fluorouracil	Phase 3	Ongoing	Poland, France, Denmark + 7 more

Drugs in Incyte Corporation trials

41 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 1 more in the trial list above.

Conditions in Incyte Corporation trials

43 conditions

Solid Tumors6Chronic Graft-versus-host-disease5Myeloproliferative Neoplasms5NonSegmental Vitiligo4Hidradenitis Suppurativa (HS)3 Atopic Dermatitis3 Hidradenitis Suppurativa3 Ovarian Cancer2Prurigo Nodularis2Pregnancy Related2 Healthy Participants2 Follicular Lymphoma1 Marginal Zone Lymphoma1 Diffuse Large B-cell Lymphoma1 Large B-Cell Lymphoma1 Diffuse Large B-Cell Lymphoma1Essential Thrombocythemia1Advanced Solid Tumors1 Metastatic Solid Tumors1 Anemia1Post-essential Thrombocythemia Myelofibrosis1Post-polycythemia Vera Myelofibrosis1Immune Thrombocytopenia1 B-Cell Malignancies1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	47	27
Clinical trials in UK	28	13
Clinical trials in China	7	3
Clinical trials in Ireland	6	2
EU register (CTIS)	6	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Solid Tumors

Sponsor	Trials
EMD Serono Research & Development Institute	2
ORIC Pharmaceuticals	2
Zai Lab (Shanghai)	2
Jacobio Pharmaceuticals	2
Mabwell (Shanghai) Bioscience	2
Hansoh BioMedical R&D Company	2
Shandong Suncadia Medicine	2
Shionogi	1
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	1
Fortvita Biologics (USA)Inc	1

Sponsors with the most current trials registered for this condition.

Questions about Incyte Corporation trials

How many clinical trials does Incyte Corporation sponsor?

Incyte Corporation is the lead sponsor of 53 current trials on ClinicalTrials.gov in our USA, UK, China and Ireland registers, and 6 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Incyte Corporation trials recruiting?

Yes. 28 of its 53 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Incyte Corporation testing?

Its current trials name 41 drugs and biologicals as interventions. The most frequent are Ruxolitinib (16), Povorcitinib (9), Axatilimab (5), Bevacizumab (4) and INCA33890 (4). The number in brackets is how many of its trials name each drug.

Does Incyte Corporation have clinical trials in Ireland?

Yes. 6 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Incyte Corporation clinical trials